Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms Clinical Trial

Official title:

An Open-label Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02145741
• Other study ID #: 1280.15
• Status: Completed
• Phase: Phase 1
• Start date: June 11, 2014
• Est. completion date: July 14, 2023

Study information

• Verified date: July 2023
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open-label dose escalation phase I trial, 1280.15, is with the first administration of BI 836845 in Japanese patients with various types of advanced solid tumours. The rationale behind this study is to identify the maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours as weekly intravenous administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 14, 2023
• Est. primary completion date: July 1, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion criteria:

Patients who meet all of the following inclusion criteria by the judgment of investigator are eligible to receive the study treatment:

1. Patients with cytologically or histologically confirmed solid tumours that are refractory to standard therapy, for whom no standard therapy of proven efficacy exists, or who are not amenable to establish treatment options

2. Age >=20 years old

3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

4. Written informed consent that is consistent with Good Clinical Practice (GCP) guidelines

Exclusion criteria:

Patients who apply any of the following exclusion criteria by the judgment of investigator are not eligible to receive the study treatment:

1. Active infectious disease to be incompatible with the study treatment

2. Patients who do not have sufficient major organ function and meet any of the following test results at screening period

• Cardiac left ventricular function with resting ejection fraction <=50% as determined by echocardiography (ECHO) or multiple-gated acquisition scan (MUGA)

• Absolute neutrophil count <1500/µL

• Platelets <100 000/µL

• Total bilirubin >1.5 × the upper limit of normal (ULN)

• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 × ULN (in case of known liver metastases, AST and/or ALT >5 × ULN)

• Creatinine >1.5 × ULN

• Haemoglobin <9 g/dL

• HbA1c >=8% and fasting glucose >8.9 mmol/L (>160 mg/dL)

3. Serious illness or concomitant non-oncological disease including severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may compromise the safety of the patient during the study, affect the patient's ability to complete the study, or interfere with interpretation of study results considered by the investigator to be incompatible with the study treatment

4. History of thrombosis (except tumour invading great vessels) within 1 year before start of study treatment or if concurrent anticoagulation required

5. Patients not recovered from any therapy-related toxicities from previous chemotherapies, hormonal therapies, immunotherapies, molecular-targeted therapies, or radiotherapies to Common Terminology Criteria for Adverse Events (CTCAE) grade <=1

6. Patients who have not recovered from any previous surgery and major surgery within the last 4 weeks before start of study treatment

7. Patients with untreated or symptomatic brain metastases.

8. Patients who have been treated with any of the following within 4 weeks before start of study treatment: chemotherapies, immunotherapies, radiotherapies (within 2 weeks before start of study treatment for local palliative radiotherapies for the treatment of brain metastasis or extremities), biological therapies, molecular-targeted therapies, hormonal therapies for breast cancer within 2 weeks before start of study treatment, or treatment with other investigational drugs.

9. Patients who have used any investigational drug within 4 weeks before start of study treatment or who have planned concomitantly use with the trial.

10. Patients unable to comply with the clinical trial protocol (CTP)

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Xentuzumab, low dose, every week (qw)
Patient to receive low dose of Xentuzumab IV
• Xentuzumab, middle dose, qw
Patient to receive middle dose of Xentuzumab IV
• Xentuzumab, high dose, qw
Patient to receive high dose of Xentuzumab IV

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital East	Chiba, Kashiwa

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours (as identified by the number of patients with dose-limiting toxicities(DLTs))		21 days

External Links

•   Related Info